Aprogen, Inc
Financials
Valuation Metrics
Aprogen, Inc's Market Cap is ₩611B. At end of 2025 it was ₩164B. Ranked #1591 of 2,436 in KR market (top 65%), #657 of 787 on KOSPI (top 83%), #263 of 365 in Capital Goods (top 72%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 61.11B KRW | KR#1,591/2,436 Sec#263/365 |
| Revenue | 127.54B KRW | KR#1,255/2,436 Sec#211/365 |
| Net Income | -138.56B KRW | KR—/2,436 Sec—/365 |
| Total Assets | 696.52B KRW | KR#592/2,436 Sec#110/365 |
| Net Assets | 430.82B KRW | KR#557/2,436 Sec#100/365 |
| Employees | 296 | KR#795/2,436 Sec#140/365 |
| Value | ||
| P/B | 0.14x | KR#33/2,436 Sec#9/365 |
| P/S | 0.48x | KR#895/2,436 Sec#125/365 |
| FCF Yield | -64.31% | KR—/2,436 Sec—/365 |
| Profitability | ||
| ROE | -32.16% | KR#2,182/2,436 Sec#323/365 |
| ROA | -19.89% | KR#2,231/2,436 Sec#334/365 |
| Op. Margin | -73.47% | KR#2,279/2,436 Sec#341/365 |
| Revenue Growth | 35.79% | KR#406/2,436 Sec#73/365 |
| Financial Health | ||
| Debt Ratio | 61.67% | KR#209/2,436 Sec#22/365 |
| Total Debt | 185.58B KRW | KR#514/2,436 Sec#92/365 |
| FCF | -39.30B KRW | KR#2,043/2,436 Sec#299/365 |
| Cash | 34.54B KRW | KR#926/2,436 Sec#159/365 |
| Current Ratio | 0.85x | KR#1,996/2,436 Sec#316/365 |
| Performance | ||
| 1Y Return | 317.07% | KR#21/2,436 Sec#6/365 |
| 1M Return | 3.19% | KR#671/2,436 Sec#62/365 |
| From 52W High | -66.79% | KR#2,000/2,436 Sec#303/365 |
| 1Y MDD | -97.31% | KR#2,435/2,436 Sec#365/365 |
| Trading | ||
| Volume | 111,498 shares | KR#796/2,436 Sec#140/365 |
| Foreign Own. | 6.46% | KR—/2,436 Sec—/365 |
| Per Share | ||
| EPS | -3,403 KRW | KR—/2,436 Sec—/365 |
| BPS | 117,663 KRW | KR#115/2,436 Sec#21/365 |
Company Info
Aprogen, established in 1971 and listed in 1995, completed a merger with a biopharmaceutical development company in 2022. Its subsidiary, Aprogen Biologics, formed a biopharmaceutical division in 2022, while N2TEC specializes in semiconductor component manufacturing and sales. Another subsidiary, APTEN, is engaged in geothermal heating/cooling, fuel cells, lithium, brain disease treatment, and virtual asset businesses. The company maintains a diversified business portfolio including hardfacing, steel, pharmaceuticals, insulation, bio, semiconductors, and renewable energy. Aprogen is headquartered in Seongnam-si, Gyeonggi-do.